Pharmaceutical Executive Daily: Pharma Industry's AI Adoption
Mar 04, 08:50 PM
Share
Subscribe
In today’s Pharmaceutical Executive Daily, Antengene and UCB enter a billion-dollar global licensing agreement for a bispecific T-cell engager, Teva signs a $400 million strategic growth capital agreement with Blackstone Life Sciences, and industry leaders explore the technological renaissance driven by AI integration.